Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage
Phase of Trial: Phase III
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Nimodipine (Primary) ; Nimodipine
- Indications Cerebral ischaemia; Subarachnoid haemorrhage
- Focus Registrational; Therapeutic Use
- Acronyms NEWTON 2
- Sponsors Edge Therapeutics
- 01 Aug 2017 According to an Edge Therapeutics media release, the company look forward to the pre-planned futility analysis in late 2017, top-line efficacy interim analysis results in the first quarter of 2018 and top-line results from the full study in late 2018.
- 03 May 2017 According to an Edge Therapeutics media release, the company has activated the first clinical site in Europe in this trial.
- 17 Feb 2017 According to the Edge Therapeutics media release, data will be presented at the International Stroke Conference (ISC) 2017.